Cystic angiomatosis (CA) is a rare disease characterized by the proliferation of vascular and lymphatic channels lined by a single layer of endothelial cells. CA may present with isolated skeletal or visceral disease. There is no consensus for the standard of care in these patients, and diverse regimens for CA have been reported, including observation, surgery, radiation, and a variety of medical therapies. We present a case of multifocal, isolated skeletal CA, treated with close observation alone and review the literature. We suggest that these cases may be safely followed without intervention and may be stable for prolonged periods of time.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001750DOI Listing

Publication Analysis

Top Keywords

cystic angiomatosis
8
close observation
8
isolated skeletal
8
asymptomatic skeletal
4
skeletal cystic
4
angiomatosis managed
4
managed conservatively
4
conservatively close
4
observation cystic
4
angiomatosis rare
4

Similar Publications

Article Synopsis
  • Von Hippel-Lindau is a rare genetic disorder with an autosomal dominant inheritance pattern, leading to multiple vascular tumors, especially in the brain, eyes, and organs.
  • The disease can manifest at any age, with retinal tumors often being one of the first signs; MRI and fluorescein angiography are key diagnostic tools.
  • A case study highlights a woman in her late 30s with vision loss, revealing various eye and kidney abnormalities, including cystic lesions in her brain and elevated urine protein levels.
View Article and Find Full Text PDF

Background: To investigate the unique properties of clinical manifestation and radiological imaging for differential diagnosis of optic nerve hemangioblastoma (ONH) from adult optic nerve glioma (ONG) prior to surgical resection.

Methods: ONH and adult ONG patients were recruited from 2012 to 2022.

Results: A total of seven ONH patients (8 eyes) and 23 adult ONG patients (24 eyes) were assessed.

View Article and Find Full Text PDF
Article Synopsis
  • - The LITESPARK-004 study is testing the hypoxia-inducible factor-2α inhibitor, belzutifan, for its effectiveness in treating tumors associated with von Hippel-Lindau disease, specifically focusing on patients with central nervous system (CNS) haemangioblastomas after additional follow-up.
  • - A total of 61 patients, with a majority having CNS haemangioblastomas, were enrolled in this phase 2 study across multiple cancer centers in four countries, and they received oral belzutifan until there were unacceptable side effects or disease progression.
  • - The study assesses the antitumor activity by evaluating patient responses using two different methods based on tumor measurements and is ongoing, with results still being
View Article and Find Full Text PDF

Rationale: Hemangioblastomas occur both sporadically and as an important component of von Hippel-Lindau (VHL) disease. The typical MRI features of hemangioblastoma are cysts with enhanced cystic wall nodules in the cerebellum or lesions with uniform enhancement on the surface or inside the spinal cord. If there is edema around hemangioblastoma, it is easy to be misdiagnosed as brain metastasis on MRI.

View Article and Find Full Text PDF

Von Hippel-Lindau (VHL) syndrome is a multi-organ neoplastic disease characterized by highly vascular and cystic tumors in the central nervous system (CNS), retina, and visceral lesions, which are mainly caused by germline mutations in . We aimed to detect novel mutations in gene in families with VHL. Here, a large consanguineous four-generation family with variant phenotypes of VHL syndrome was recruited, and its molecular genetics were tested Sanger sequencing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!